Member Info for dactions

Blessed22 - thanks for ********** link - it's always worth seeing the charts at possible break-out points.
8 minutes into presentation.

Now coming up to mid September, does anyone have any current news on trading or the Court case ?

Perhaps it could be worth raising this question on the Investor Meet Company platform although I've been disappointed with this platform for other shares.

I'm sure the Daily Mail article was based on Sajid Javid's briefings to the media. The arguments are not straightforward, in that he could at a stroke reduce most PCR costs by 20% vat the government is happily taking on most sales but those suggestions get an immediate put-down whenever raised. In my opinion, they still want to suppress foreign travel numbers one way or another - so I feel on balance the PCR tests will remain and our income will continue to accrues.

However, the sp is more often than not based on public sentiment and so I expect continued weakness in the share price for the foreseeable future. I am more concerned that alternative testing products do not seem to be on the agenda at all at MHC right now. I can well understand that the current Covid business may be taking management time but now is the time to get other products into Boots or Lloyds stores whilst we have the good name & pricing points for the Covid tests.

It's not as if we had no other products, we have the original Concepta fertility testing 'mylotus' and whilst I know sales were abysmal, the product itself compared really well against competitors. Isn't this the kind of area where Boots marketing would excel ? Right now, we are a one trick pony and unless something really good comes up in figures later this month, without other product news I'm not feeling as positive as I once did.

I'd agree Stokey but it's the very thing that gets thrown out when you're on a 'cost-cutting mission'.

Always good to close the week dreaming ;-)

The really good thing about this morning's RNS is that it confirms in my mind that Polygon are going to stay the ride for the Phase III results - as I am !

I see share ** prophets have made another buy recommendation today. But whatever the merits of TPG or SAG and the Investor presentation next Tuesday (14th) , I can't see the sp bouncing strongly upwards - can you ?

That's a long way from here relatively speaking. but I'd love to think it possible.

Well - aimofthegame - I was a 6p placee and have added at 5p and 4.5p - I'm looking for 11p.

I reckon given we're now in September and only 4 months away from knowing their likely end year results (they've been incredibly fast keeping us informed) - barring a war, the results are going to be exceptional and as they've promised us a dividend, we can definitely expect a good run up with the sp.

Might be able to trade in & out in that time but I'm thinking this will be slow but steady run up and so I think I'll stay put. GLA

I agree Stokey12 - as for me, I really don't know what to make of TPG - I was right in the past that they were hopeless under Cartmell - and I was right to see a bid coming although I thought it would be 6p - but for all that I don't have a clue what to expect next week ?

What price would you like to achieve in the short term - aimofthegame ?

With a purchase yesterday afternoon of 180,000 shares at a round 40p, I'm pleased someone else (or II) believes like me that 40p is a great price to pay. I'm quite sure in my mind that sentiment will change and the sp rise once again. The fundamentals have changed at FUM - the ducks are all lined up - it just needs a bit more meat on the bone when the company announces the figures next week.

We know we're not yet in manufacturing MED3000 but other news can boost the sp and it's up to the BoD to recognise that. Let's see.

GLA

A lot now rides on the September 14th announcement - dismal figures and the sp falls but Science group in the meantime picks up the remaining 5% shares bringing it to 29.9%. Unless there is another bidder, I can't see, short of spectacular and believable figures are announced, that shareholders will see much in the way of sp growth for some time.

What's likely to happen now ?
Pre. the initial notice of the Science Group interest 3 weeks ago, the shares were around 4.6p and pre. the Phil Cartmell departure, they were even worse at 3.6p. If Science group really do sit on the sidelines, then I would expect a fall back to around 4p but surely, they'll want to pick up another 5% bringing them up to the 29.9% limit given the hit the sp is taking right now.

On past performance, I can't see the interim results to be published 14th September to be anything other than dismal which will keep the sp down but if there really is some good stuff announced, then the sp could really rise beyond the 6.5p offer level even if it's only a temporary spike.

Bucolic - sounds more like a dog food :)
But they were talking at one time something like 'eroxen' but I think words like that are already taken - how about some latin such as 'eroque' - meaning "I will be" or a word I've made up 'evoque' - I can see either of those working well - you've seen it here first.

Aw shucks ! TLWilliams - stop being sensible - even though we're grown adults - we can't possibly - to quote you - "wait a few more months for the results and analysis from the company's Phase III clinical trials".

With nessab, Meelie waking up early to check pre-market for Synairgen announcements, not to forget Tornodotony actually putting his alarm at 7am - and GGGT feeling the same, you're in danger of sounding like the redoubtable Woodstock opining that: his only problem with the stock market is remaining mindful. It's easy to wish life away waiting for the next Rns.

This is the period of no news - the quiet before the storm - or more hopefully quite the opposite in meaning - the jubilation - the big one - in all my 40 years of investing and as a real long term investor in Synairgen, pre-Astra Zenica days, I don't think I've ever felt so patient and yet so expectant. Perhaps I'll set my alarm too for 7am Monday to Friday.

GLA

I'm getting a sad character in need of remembering what's important in life, because I've noticed that I've started checking my phone first thing every morning now looking for a Synairgen RNS !!

Barder promised us this week that more contracts will follow this year - it seems to me that once in production, publicity will get round markets just like Viagra did. If they can find a punchy product name, sales will take off. That time cannot be far away now. I foresee the sp above £1 once sales start - after that who knows - hopefully it'll be big.

GLA

I see LB and his associates are trying to trash the LSE Futura threads. I have a lot of green filter boxes showing up and I guess they're from them - I have no idea what they're saying and as a LTH, I have not the slightest interest in their crass comments. Got that off my chest . . .

Sceptics are allowed but we need balance now. This share has a lot of potential for us - not just a few coppers here or there but a substantial uplift sooner or later. They've achieved, amazingly by error almost, finding that the delivery system of their products , ie. Dermasys has a beneficial stimulus to the ***** and have proved this albeit by odd results via a 1000 patients trial. They've been awarded the EU certification 'CE' marking to sell this over the counter.

The CE mark will for the current period be good for sales in the UK without any further work.

The United States FDA has only asked for a limited trial to see if the product holds good over a six months period with a max of 100 patients, 20 I believe must be Black Americans. The funding for this has been met from the earlier 40p placing which is also funding manufacturing by FUM - if that's what it comes to rather than out-licensing to a suitable pharma.

The BoD has achieved an excellent tie-up with the Chinese who are funding the market there and in adjacent territories.

This week we saw the news of the somewhat similar tie-up with the US based M8 Pharmaceuticals to serve the Latin American markets, particularly Mexico and Brazil. A company much larger than FUM, Pharmonia in the UK signed up with M8 to get their products into the Mexico and Brazil markets. The website says:
"m8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico. m8 aims to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, Respiratory, Cardiometabolic, Rheumatology, Gastroenterology, Onco-hematology and Orphan Diseases. "

Note M8's mention of: high-value innovative and proven therapies. This perfectly describes MED3000 .

Perhaps because of the nature of FUM's product, dealing with sexual health and Erectile Dysfunction, their shares are still under the radar. There is no other proven product that has gone through the prolonged clinical trials and procedures as has FUM and has achieved a European Union 'CE' marking enabling it now to immediately sell MED3000 on the over the counter market throughout the EU and UK - moreover the CE mark is recognised in the massive Turkey market too.

Barder promised us this week that more contracts will follow this year - it seems to me that once in production, publicity will get round markets just like Viagra did. If they can find a punchy product name, sales will take off. That time cannot be far away now. I foresee the sp above £1 once sa